NOVARTIS PHARMACEUTICALS UK LIMITED
Company Information
- Company Number
- 00119006
- Registered Address
- 2nd Floor, The Westworks Building White City Place, 195 Wood Lane, London, United Kingdom, W12 7FQ
- Status
- Active
- Employee Count
- 918
- Turnover
- £713,360,000
- EBITDA
- £38,404,000
Additional Details
- Company Type
- Private limited Company
- Incorporated On
- 8 December 1911
- Nature of Business
- 21100 - Manufacture of basic pharmaceutical products
- Industries
- Life Sciences And Medical Technology
- Region
- London
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 22 Jul 2025 | 55 | 14% | 46% | 40% | 26% |
| 01 Jan 2024 - 30 Jun 2024 | 22 Jul 2024 | 69 | 11% | 31% | 58% | 13% |
| 01 Jul 2023 - 31 Dec 2023 | 17 Jan 2024 | 63 | 16% | 30% | 54% | 16% |
| 01 Jan 2022 - 30 Jun 2022 | 20 Jul 2022 | 58 | 12% | 49% | 39% | 16% |
| 01 Jul 2021 - 31 Dec 2021 | 25 Jan 2022 | 52 | 16% | 53% | 31% | 12% |
| 01 Jan 2021 - 30 Jun 2021 | 15 Jul 2021 | 55 | 15% | 51% | 34% | 21% |
| 01 Jan 2020 - 30 Jun 2020 | 29 Jul 2020 | 53 | 32% | 35% | 33% | 35% |
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | 48 | 47% | 28% | 24% | 44% |
| 01 Jan 2018 - 30 Jun 2018 | 27 Jul 2018 | 91 | 15% | 39% | 46% | 59% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Standard payment terms are 60 days following the invoice receipt at Novartis. Depending on the commercial situation, variations to these standard terms might be negotiated on some occasions.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
120
Dispute Resolution Process
First point of contact for disputes or concerns is the Procure-to-Payment team within the Novartis Global Services Centre, for which all suppliers have contact details of. In addition to that, new suppliers receive an on-boarding pack, which includes information on issue raising and related points of contact. When an invoice dispute is received, it should be resolved at point of contact with the Procure-to-Payment team. If this is not possible, the query will be escalated to the Business contact and relevant senior Finance contact or P2P Business Partner. Timelines of escalation vary, depending on the nature of the query. When resolved, the invoice will be available for payment on the next standard payment run.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
Novartis Pharmaceuticals UK Limited is a leading pharmaceutical company based in the UK. It is a subsidiary of Novartis, a global healthcare company with a strong focus on research and development.
The company's sustainability program is centered around four key pillars: access to healthcare, environmental sustainability, ethical business practices, and employee well-being. This program is aligned with the United Nations' Sustainable Development Goals and aims to make a positive impact on society and the environment.
Novartis Pharmaceuticals UK Limited offers a wide range of products and services in various therapeutic areas such as cardiovascular, oncology, respiratory, and neuroscience. Their innovative medicines and treatments are designed to improve the quality of life for patients and contribute to the advancement of healthcare.
Some key people at Novartis Pharmaceuticals UK Limited include Haseeb Ahmad, the UK Country President, and Dr. Julie Gerberding, the Chief Patient Officer and Executive Vice President of Strategic Communications, Global Public Policy and Population Health. They are joined by a team of highly skilled and dedicated professionals who strive to make a difference in the healthcare industry.
The company's registered office address is in Surrey, UK, and their website address is https://www.novartis.co.uk/. Customers and stakeholders can contact the company through their website or by phone at +44 (0) 1276 698370. Novartis Pharmaceuticals UK Limited is committed to making a positive impact through its sustainable practices and providing innovative healthcare solutions to improve lives.
